Satisfaction and regret after radical prostatectomy procedures studiedAugust 27, 2008New study published in European Urology Studies have shown that approximately 16% of patients with localised prostate cancer regret their treatment choice. European Urology (http://www.europeanurology.com), the official journal of the European Association of Urology, will be publishing an article by J.W. Moul et al. comparing differences in satisfaction and regret between patients who underwent open retropubic radical prostatectomy and robot-assisted laparoscopic radical prostatectomy. The study, carried out at the Duke University Medical Center, Durham (US), aimed to identify independent predictors for satisfaction and regret after radical prostatectomy so that patients can be counselled more adequately. A total of 400 patients responded, the majority of whom were satisfied. The article title is 'Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy'.
This is the first study addressing the impact of a surgical approach to prostatectomy on satisfaction and regret. Sociodemographic variables and disease-specific, health-related quality of life were important variables associated with satisfaction and regret. The authors found that undergoing robot-assisted laparoscopic radical prostatectomy (RALP) is independently associated with more frequent dissatisfaction and regret, about 3-4 times more than patients undergoing retropubic radical prostatectomy (RRP). The authors state that patients who chose the innovative, less invasive RALP may have higher expectations for their postoperative health-related quality of life compared to patients choosing more traditional surgery. Therefore, even if both groups achieved similar function and bother scores, the RALP group still experienced a higher level of dissatisfaction and regret than the RRP group. African-American race was significantly associated with regret. This may be caused by a possible broad black-white perception gap in health care. It may also be caused by the fact that patients tend to give higher ratings of satisfaction to race-concordant physicians and none of the physicians in the study were African American. Further research in more diverse patient populations is needed. Also of interest is the finding that longer follow-up was independently associated with satisfaction and regret, i.e. patients tend to regret their treatment choice more if poor health-related quality of life persists over a longer period of time. The authors suggest that urologists carefully portray the risks and benefits of new technologies during preoperative counselling to minimise regret and maximise satisfaction. Elsevier | |||||||||||||||||||||
|
Related Radical Prostatectomy Current Events and Radical Prostatectomy News Articles Study shows PDE5 inhibitor more effective when used on demand in erectile dysfunction European Urology, the official journal of the European Association of Urology will be featuring the article 'Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy' by F. Montorsi et al.in the October issue, showing for the first time that vardenafil, a PDE5 inhibitor, is more efficacious when used on-demand in men with erectile dysfunction, supporting a shift towards on-demand dosing with PDE5 inhibitors in this patient group. Disparities in prostate cancer treatment suggest ways to improve care Quality of care varies greatly for the treatment of men with early-stage prostate cancer by region of the country and category of health care facility, suggesting the potential for improved patient outcomes with more standard treatment protocols. Elevated biomarkers predict risk for prostate cancer recurrence A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease. UT Southwestern urologists identify seven biomarkers that may help pinpoint prostate cancer recurrence A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found. Radiation therapy prolongs life in men with recurrent prostate cancer Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence. How advanced prostate cancer becomes resistant to androgen-deprivation therapy For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. MR imaging accurately determines prostate cancer treatment failure Dynamic contrast-enhanced MRI (DCE-MRI) plus diffusion weighted imaging (DWI) can accurately diagnose residual or recurrent prostate cancer in patients treated with high-intensity focused ultrasonic ablation, a new study shows. New blood marker may predict prostate cancer spread Researchers report finding a new blood biomarker that enables close to 98 percent accuracy in predicting the spread of prostate cancer to regional lymph nodes. First biomarker discovered that predicts prostate cancer outcome Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery. Outcome of prostate cancer surgery depends on the experience of the surgeon According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience. More Radical Prostatectomy Current Events and Radical Prostatectomy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||